Corbus CRB-601-01 (Solid Tumors) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an experimental drug called CRB-601 (the study drug) is a safe and effective option for people who have cancers with advanced solid tumors that did not improve with standard treatment.
Advanced Solid Tumor Cancers
Who Can Participate in the Study?
Adults ages 18-64 who:
- Are diagnosed with an advanced or metastatic solid tumor
- Had their disease progress after at least 1 line of previous treatment
For more information about who can join this study, please contact the Center for Cancer Immunotherapy at CCI-TrialReferrals@duke.edu.
What is Involved?
If you choose to join this study, you will get an assignment to 1 of 3 different dose levels of the study drug. These dose levels might be:
- 3 milligrams for each kilogram of body weight (3 mg/kg); OR
- 10 mg/kg; OR
- 30 mg/kg
The dose level you receive will depend on when you join the study. The study team can let you know what dose level is open when you make your decision.
The study drug is given as an intravenous (IV) infusion every 2 weeks.
Study Details
